(+/-)-Ethyl 2-Methyl-4-(thiophen-3-yl)-1,4-dihydrobenzo[4,5]-imidazo[1,2-a]pyrimidine-3-carboxylate

ID: ALA3785618

Chembl Id: CHEMBL3785618

PubChem CID: 127033325

Max Phase: Preclinical

Molecular Formula: C18H17N3O2S

Molecular Weight: 339.42

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1ccsc1

Standard InChI:  InChI=1S/C18H17N3O2S/c1-3-23-17(22)15-11(2)19-18-20-13-6-4-5-7-14(13)21(18)16(15)12-8-9-24-10-12/h4-10,16H,3H2,1-2H3,(H,19,20)

Standard InChI Key:  FRCVFFDEURQUBC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3785618

    ---

Associated Targets(Human)

ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2A Tclin Adenosine A2a receptor (16305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA2B Tclin Adenosine A2b receptor (7672 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA3 Tchem Adenosine A3 receptor (15931 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 339.42Molecular Weight (Monoisotopic): 339.1041AlogP: 3.95#Rotatable Bonds: 3
Polar Surface Area: 56.15Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 10.87CX Basic pKa: 6.15CX LogP: 3.58CX LogD: 3.55
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.73Np Likeness Score: -1.91

References

1. El Maatougui A, Azuaje J, González-Gómez M, Miguez G, Crespo A, Carbajales C, Escalante L, García-Mera X, Gutiérrez-de-Terán H, Sotelo E..  (2016)  Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.,  59  (5): [PMID:26824742] [10.1021/acs.jmedchem.5b01586]
2. Mallo-Abreu A, Majellaro M, Jespers W, Azuaje J, Caamaño O, García-Mera X, Brea JM, Loza MI, Gutiérrez-de-Terán H, Sotelo E..  (2019)  Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition.,  62  (20): [PMID:31557025] [10.1021/acs.jmedchem.9b01340]
3. Mallo-Abreu A, Prieto-Díaz R, Jespers W, Azuaje J, Majellaro M, Velando C, García-Mera X, Caamaño O, Brea J, Loza MI, Gutiérrez-de-Terán H, Sotelo E..  (2020)  Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A2B Adenosine Receptor Antagonists.,  63  (14): [PMID:32573250] [10.1021/acs.jmedchem.0c00564]

Source